Open AccessDrug discovery oncology in a mouse: concepts, models and limitations
Author(s) -
Jason E. Long,
Maja Jankovic,
Danilo Maddalo
Publication year - 2021
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.2144/fsoa-2021-0019
Subject(s) - drug discovery , crispr , workflow , identification (biology) , computational biology , genome editing , drug development , computer science , medicine , bioinformatics , drug , biology , pharmacology , genetics , botany , database , gene
The utilization of suitable mouse models is a critical step in the drug discovery oncology workflow as their generation and use are important for target identification and validation as well as toxicity and efficacy assessments. Current murine models have been instrumental in furthering insights into the mode of action of drugs before transitioning into the clinic. Recent advancements in genome editing with the development of the CRISPR/Cas9 system and the possibility of applying such technology directly in vivo have expanded the toolkit of preclinical models available. In this review, a brief presentation of the current models used in drug discovery will be provided with a particular emphasis on the novel CRISPR/Cas9 models.